Filtered By:
Specialty: Pharmaceuticals
Education: Conferences
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
ASA: Racial Differences Seen in Treatment of Common Poststroke Sequelae
MONDAY, Feb. 6, 2023 -- Considerable racial differences are seen in the treatment of common poststroke sequelae, according to a study presented at the American Stroke Association International Stroke Conference, held from Feb. 8 to 10 in...
Source: Drugs.com - Pharma News - February 6, 2023 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news
American Stroke Association, Feb. 9-11
The annual International Stroke Conference of the American Heart Association/American Stroke Association was held from Feb. 9 to 11 in New Orleans and attracted participants from around the world, including cerebrovascular research and practice...
Source: Drugs.com - Pharma News - February 22, 2022 Category: Pharmaceuticals Source Type: news
ASA: Scoring System May Predict Stroke Risk in COVID-19 Inpatients
TUESDAY, Feb. 8, 2022 -- A new scoring system helps predict the risk for stroke among adults hospitalized with COVID-19, according to a study presented at the American Stroke Association International Stroke Conference, held from Feb. 9 to 11 in New...
Source: Drugs.com - Pharma News - February 8, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
American Stroke Association, March 17-19
The annual International Stroke Conference of the American Heart Association/American Stroke Association was held virtually this year from March 17 to 19 and attracted participants from around the world, including cerebrovascular research and...
Source: Drugs.com - Pharma News - March 29, 2021 Category: Pharmaceuticals Source Type: news
ASA: Women at Greater Risk for Poststroke Depression
FRIDAY, March 19, 2021 -- Female stroke patients have a higher risk for poststroke depression (PSD) than male stroke patients, according to two studies presented at the American Stroke Association International Stroke Conference, held virtually from...
Source: Drugs.com - Pharma News - March 19, 2021 Category: Pharmaceuticals Source Type: news
ASA: Retinopathy Linked to Increased Risk for Stroke, Dementia
THURSDAY, March 11, 2021 -- Retinopathy is associated with an increased risk for stroke and dementia, according to a study presented at the American Stroke Association International Stroke Conference, held virtually from March 17 to 19.
Michelle P....
Source: Drugs.com - Pharma News - March 11, 2021 Category: Pharmaceuticals Source Type: news
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
ASA: Herpes Zoster Vaccine May Reduce Risk for Stroke
WEDNESDAY, Feb. 12, 2020 -- Vaccination with zoster vaccine live (ZVL) is associated with a reduced risk for stroke among older adults, according to a study to be presented at the American Stroke Association International Stroke Conference, held...
Source: Drugs.com - Pharma News - February 12, 2020 Category: Pharmaceuticals Source Type: news
ASA: No Decline Seen in Active Smoking for Stroke Survivors
WEDNESDAY, Feb. 12, 2020 -- From 1999 to 2016, there was no decrease in the rate of active smoking among stroke survivors, according to a study to be presented at the American Stroke Association International Stroke Conference, held from Feb. 19 to...
Source: Drugs.com - Pharma News - February 12, 2020 Category: Pharmaceuticals Source Type: news
Hawaii Convention Center to host major medical conference
More than 4,500 healthcare professionals from 50 countries will converge on the Hawaii Convention Center for the American Stroke Association's International Stroke Conference, to be held Feb. 6-8, the center announced Tuesday.
It's the second time Hawaii is hosting the conference.
"The center first hosted the International Stroke Conference in 2013, and we are looking forward to welcoming this world-class meeting back to Hawaii, kicking off a year of major medical and scientific gatherings here,"…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 16, 2019 Category: Pharmaceuticals Authors: A. Kam Napier Source Type: news
More stroke patients may receive crucial treatments under new guideline
More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the American Heart Association/American Stroke Association. The guideline, based on the most recent science available, was published in the Association's journal Stroke, and released during the American Stroke Association's International Stroke Conference 2018, the premier global meeting for researchers and clinicians dedicated to the prevention and treatment of stroke.
Source: World Pharma News - January 24, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
